Valerie Kvaternick
Valerie Kvaternick has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
J. Fischer
Pharmacokinetics and Drug Metabolism, Merial Limited, North Brunswick, NJ, USA
1 shared publicationJames Fischer
1 shared publicationJill Wortmann
1 shared publicationJoseph Rosentel
Merial Limited, Pharmaceutical Research and Development, Duluth, GA 30096, USA
1 shared publicationM. Pollmeier
Saint Vulbas Research Center, Merial SAS, Parc Industriel de la Plaine de l'Ain, Saint Vulbas, France
1 shared publication- Martin Knaus
Merial GmbH, Kathrinenhof Research Center, 83101, Rohrdorf, Germany,
1 shared publication
Latest Publications
- Open Access
- 1 April 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 202 (1-2) , 2-9
Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel
- 1 April 2014
- Published by Elsevier in Veterinary Parasitology
- Vol. 202 (1-2) , 2-9
Open AccessPharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel
- 1 July 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 854 (1-2) , 313-319
Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma
- 1 July 2007
- Published by Elsevier in Journal of Chromatography B
- Vol. 854 (1-2) , 313-319
Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma
- 5 April 2007
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 30 (3) , 208-217
Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses
The primary objective of this study was to determine the pharmacokinetic profile of firocoxib, a novel second generation coxib, in horses. Horses were administered either a single oral or intravenous dose of firocoxib at 0.1 mg/kg in a two‐period crossover study with 12 animals. The dosage was based on previously determined pharmacodynamic parameters. Oral firocoxib was well absorbed with an average bioavailability (absolute) of 79% and aCmaxof 75 ng/mL at 3.9 h. The average elimination half‐life was 30 h. Following intravenous administration the averageCmaxwas 210 ng/mL and the elimination half‐life was 34 h. The area under the curve [AUC(0–tlast)] was 1.8 μg·h/mL for the oral dose and 2.3 μg·h/mL for the intravenous dose. Firocoxib was widely distributed with a volume of distribution value of 1.7 L/kg for the intravenous dose. Biotransformation of firocoxib was via dealkylation and glucuronidation to inactive metabolites, namely descyclopropylmethylfirocoxib and its glucuronide conjugate. Urinary excretion was the major route of elimination, and the clearance rate was 37 mL/h/kg.
- 5 April 2007
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 30 (3) , 208-217
Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses
The primary objective of this study was to determine the pharmacokinetic profile of firocoxib, a novel second generation coxib, in horses. Horses were administered either a single oral or intravenous dose of firocoxib at 0.1 mg/kg in a two‐period crossover study with 12 animals. The dosage was based on previously determined pharmacodynamic parameters. Oral firocoxib was well absorbed with an average bioavailability (absolute) of 79% and aCmaxof 75 ng/mL at 3.9 h. The average elimination half‐life was 30 h. Following intravenous administration the averageCmaxwas 210 ng/mL and the elimination half‐life was 34 h. The area under the curve [AUC(0–tlast)] was 1.8 μg·h/mL for the oral dose and 2.3 μg·h/mL for the intravenous dose. Firocoxib was widely distributed with a volume of distribution value of 1.7 L/kg for the intravenous dose. Biotransformation of firocoxib was via dealkylation and glucuronidation to inactive metabolites, namely descyclopropylmethylfirocoxib and its glucuronide conjugate. Urinary excretion was the major route of elimination, and the clearance rate was 37 mL/h/kg.